Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy.

Trial Profile

Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin (CI-1008) In The Treatment For Pain Associated With Diabetic Peripheral Neuropathy.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Nov 2016 Results of a retrospective analysis from NCT00394901, NCT00553475, NCT00407745, NCT00424372, NCT00553280, NCT01202227 studies, published in the Clinical Drug Investigation
    • 28 Oct 2010 Based on results from this and nine other trials pregabalin has been approved by the Japanese Ministry of Health, Labour, and Welfare, according to a Pfizer media release.
    • 28 Oct 2010 Results from this trial have been reported in a Pfiizer media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top